Keudell Morrison Wealth Management purchased a new stake in Elevance Health, Inc. (NYSE:ELV - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 5,033 shares of the company's stock, valued at approximately $1,764,000.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Sound View Wealth Advisors Group LLC raised its position in shares of Elevance Health by 3.0% during the fourth quarter. Sound View Wealth Advisors Group LLC now owns 1,011 shares of the company's stock worth $354,000 after purchasing an additional 29 shares during the period. Fulton Breakefield Broenniman LLC raised its position in shares of Elevance Health by 3.6% during the fourth quarter. Fulton Breakefield Broenniman LLC now owns 825 shares of the company's stock worth $289,000 after purchasing an additional 29 shares during the period. Perigon Wealth Management LLC raised its position in shares of Elevance Health by 2.2% during the fourth quarter. Perigon Wealth Management LLC now owns 1,371 shares of the company's stock worth $481,000 after purchasing an additional 29 shares during the period. Savvy Advisors Inc. raised its position in shares of Elevance Health by 3.2% during the fourth quarter. Savvy Advisors Inc. now owns 979 shares of the company's stock worth $343,000 after purchasing an additional 30 shares during the period. Finally, Detalus Advisors LLC raised its position in shares of Elevance Health by 1.8% during the third quarter. Detalus Advisors LLC now owns 1,726 shares of the company's stock worth $558,000 after purchasing an additional 31 shares during the period. Institutional investors own 89.24% of the company's stock.
Analyst Ratings Changes
ELV has been the topic of a number of research reports. Wells Fargo & Company lowered their target price on Elevance Health from $424.00 to $391.00 and set an "overweight" rating on the stock in a research report on Friday, January 30th. Mizuho upped their target price on Elevance Health from $385.00 to $435.00 and gave the stock an "outperform" rating in a research report on Wednesday. Truist Financial lowered their target price on Elevance Health from $390.00 to $375.00 and set a "buy" rating on the stock in a research report on Monday, April 13th. Sanford C. Bernstein upped their target price on Elevance Health from $384.00 to $424.00 and gave the stock an "outperform" rating in a research report on Friday, April 24th. Finally, Barclays upped their target price on Elevance Health from $393.00 to $408.00 and gave the stock an "overweight" rating in a research report on Friday, April 24th. Fourteen investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, Elevance Health has an average rating of "Moderate Buy" and a consensus price target of $396.16.
View Our Latest Stock Report on Elevance Health
Elevance Health Trading Down 1.8%
Shares of Elevance Health stock opened at $389.17 on Friday. The stock has a fifty day simple moving average of $331.71 and a 200 day simple moving average of $335.84. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $408.00. The company has a market capitalization of $84.51 billion, a P/E ratio of 16.55, a price-to-earnings-growth ratio of 2.24 and a beta of 0.66. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70.
Elevance Health (NYSE:ELV - Get Free Report) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The business had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. During the same quarter in the prior year, the company posted $11.97 earnings per share. Elevance Health's revenue was up 1.5% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, sell-side analysts anticipate that Elevance Health, Inc. will post 26.94 earnings per share for the current fiscal year.
Elevance Health Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be issued a dividend of $1.72 per share. The ex-dividend date is Wednesday, June 10th. This represents a $6.88 annualized dividend and a yield of 1.8%. Elevance Health's dividend payout ratio is 29.26%.
About Elevance Health
(
Free Report)
Elevance Health, Inc NYSE: ELV is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company's strategic focus on integrated health care and benefit delivery.
Elevance's core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.
Recommended Stories
Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Elevance Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elevance Health wasn't on the list.
While Elevance Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.